Abbott Laboratories $ABT is Everett Harris & Co. CA’s 9th Largest Position

Everett Harris & Co. CA lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,458,381 shares of the healthcare product maker’s stock after selling 8,766 shares during the quarter. Abbott Laboratories accounts for 2.2% of Everett Harris & Co. CA’s investment portfolio, making the stock its 9th largest holding. Everett Harris & Co. CA owned 0.08% of Abbott Laboratories worth $182,721,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the 4th quarter worth $25,000. Harbor Capital Advisors Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $27,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth $33,000. Leonteq Securities AG acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $35,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ABT shares. Evercore lowered their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. UBS Group lowered their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Wells Fargo & Company lowered their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $90.46 on Tuesday. The stock has a market cap of $157.57 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The company’s 50-day moving average price is $92.52 and its 200 day moving average price is $108.88. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the company earned $1.09 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.